TR200100575T2 - New uses of taxoid derivatives - Google Patents
New uses of taxoid derivativesInfo
- Publication number
- TR200100575T2 TR200100575T2 TR2001/00575T TR200100575T TR200100575T2 TR 200100575 T2 TR200100575 T2 TR 200100575T2 TR 2001/00575 T TR2001/00575 T TR 2001/00575T TR 200100575 T TR200100575 T TR 200100575T TR 200100575 T2 TR200100575 T2 TR 200100575T2
- Authority
- TR
- Turkey
- Prior art keywords
- taxoid derivatives
- new uses
- relates
- taxoid
- derivatives
- Prior art date
Links
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 abstract 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 201000002313 intestinal cancer Diseases 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Bu bulus, taksoid türevlerinin yeni kullanim alaniyla ilgilidir. Bu bulus özellikle birden fazla ilaca karsi direnç gösteren P-glikoprotein üreten ve farkli dirençlere sahip hücre dizilerinde görülen anormal çogalmanin önlenmesine iliskin bir yöntemle ilgilidir. Bu tür hücreler kalin bagirsak hücrelerini temsil etmektedir. Bu bulus kapsamindaki ürün insanlar dahil, memelilerdeki kalin bagirsak kanserini tedavi etmek için kullanilabilir.This invention relates to the new use of taxoid derivatives. This invention relates in particular to a method for preventing abnormal replication in cell lines that produce P-glycoprotein that is resistant to more than one drug and has different resistance. Such cells represent thick intestinal cells. The product of this invention can be used to treat large bowel cancer in mammals, including humans.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98115650A EP0982028A1 (en) | 1998-08-20 | 1998-08-20 | New use of taxoid derivatives |
| US12384399P | 1999-03-11 | 1999-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200100575T2 true TR200100575T2 (en) | 2001-07-23 |
Family
ID=26149552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2001/00575T TR200100575T2 (en) | 1998-08-20 | 1999-08-18 | New uses of taxoid derivatives |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1105119A2 (en) |
| JP (1) | JP2002523364A (en) |
| KR (1) | KR20010079665A (en) |
| CN (1) | CN1313764A (en) |
| AU (1) | AU5742099A (en) |
| BG (1) | BG105273A (en) |
| CA (1) | CA2341191A1 (en) |
| EE (1) | EE200100082A (en) |
| HU (1) | HUP0104000A3 (en) |
| IL (1) | IL141231A0 (en) |
| MX (1) | MXPA01001721A (en) |
| NO (1) | NO20010655D0 (en) |
| SK (1) | SK2352001A3 (en) |
| TR (1) | TR200100575T2 (en) |
| WO (1) | WO2000010547A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2922107B1 (en) * | 2007-10-10 | 2010-02-26 | Aventis Pharma Sa | NEW TAXOID COMPOSITIONS |
| JP5566466B2 (en) | 2009-10-29 | 2014-08-06 | アバンテイス・フアルマ・エス・アー | Novel anti-tumor use of cabazitaxel |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2697522B1 (en) * | 1992-10-30 | 1994-11-25 | Rhone Poulenc Rorer Sa | Process for the preparation of taxane derivatives. |
| MA23823A1 (en) * | 1995-03-27 | 1996-10-01 | Aventis Pharma Sa | NEW TAXOIDS, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM |
| FR2732968B1 (en) * | 1995-04-14 | 1997-05-16 | Rhone Poulenc Rorer Sa | NOVEL TAXOIDS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
-
1999
- 1999-08-18 CA CA002341191A patent/CA2341191A1/en not_active Abandoned
- 1999-08-18 IL IL14123199A patent/IL141231A0/en unknown
- 1999-08-18 TR TR2001/00575T patent/TR200100575T2/en unknown
- 1999-08-18 JP JP2000565869A patent/JP2002523364A/en active Pending
- 1999-08-18 EE EEP200100082A patent/EE200100082A/en unknown
- 1999-08-18 MX MXPA01001721A patent/MXPA01001721A/en unknown
- 1999-08-18 CN CN99809900A patent/CN1313764A/en active Pending
- 1999-08-18 HU HU0104000A patent/HUP0104000A3/en unknown
- 1999-08-18 EP EP99944532A patent/EP1105119A2/en not_active Withdrawn
- 1999-08-18 AU AU57420/99A patent/AU5742099A/en not_active Abandoned
- 1999-08-18 WO PCT/EP1999/006292 patent/WO2000010547A2/en not_active Ceased
- 1999-08-18 SK SK235-2001A patent/SK2352001A3/en unknown
- 1999-08-18 KR KR1020017002136A patent/KR20010079665A/en not_active Withdrawn
-
2001
- 2001-02-07 NO NO20010655A patent/NO20010655D0/en unknown
- 2001-02-20 BG BG105273A patent/BG105273A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1313764A (en) | 2001-09-19 |
| HUP0104000A2 (en) | 2002-04-29 |
| NO20010655L (en) | 2001-02-07 |
| WO2000010547A3 (en) | 2000-06-29 |
| IL141231A0 (en) | 2002-03-10 |
| EE200100082A (en) | 2002-06-17 |
| CA2341191A1 (en) | 2000-03-02 |
| HUP0104000A3 (en) | 2003-01-28 |
| JP2002523364A (en) | 2002-07-30 |
| EP1105119A2 (en) | 2001-06-13 |
| MXPA01001721A (en) | 2005-06-03 |
| NO20010655D0 (en) | 2001-02-07 |
| KR20010079665A (en) | 2001-08-22 |
| WO2000010547A2 (en) | 2000-03-02 |
| AU5742099A (en) | 2000-03-14 |
| SK2352001A3 (en) | 2001-07-10 |
| BG105273A (en) | 2001-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69622871D1 (en) | TETRALIN CONNECTIONS WITH MULTI-DRUG RESISTANCE (MDR) ACTIVITY | |
| BR0111974A (en) | Protection zone selection system for a power system bus | |
| TR200401264T4 (en) | The combination of CB1-receptor-antagonist and cybutamine, pharmaceutical compositions containing them and their use in the treatment of obesity. | |
| TR199800644T2 (en) | y-RAR antagonist ligand or alpha-RAR antagonist ligand as an apoptosis inhibitor. | |
| TR200100575T2 (en) | New uses of taxoid derivatives | |
| Allison | Mutagen specificity at the ad-3A and inositol loci in Neurospora crassa | |
| Castellani | Epidemiology and quantitation of environmental risk in humans from radiation and other agents | |
| Lincoln | Proclamation of a National Fast Day; Meditation on the Divine Will | |
| Stamler | Who will be effective as a clinical trials investigator and what are adequate incentives? Appendix 1: A proposed mechanism and set of criteria for the evaluation of the scientific contribution of individual investigators in collaborative studies, including large clinical trials | |
| BR9913071A (en) | Use of a compound derived from taxoid | |
| Johnson | Bayesian Nash equilibria in a public-goods experiment with a provision point | |
| Varga et al. | Ageing, Safety and Legal Aspects of Cableways in Austria | |
| Trivedi et al. | Association between Selenium (Se) intake, plasma Se levels and disease progression in HIV‐infected adults in Miami | |
| Ritz et al. | Antioxidant and immunomodulatory effects of whole food extracts | |
| Schuman | Generational Effects: Past, Present, and Future | |
| Beck | The office for human research protections and the NIH | |
| Student Government Association | Senate Bill SB-98F-1102 Change to Constitutional Statutes, Rule Nine Judiciary Rules and Procedures | |
| Hamzehloei et al. | Mutation detection in exons 1–14 of the adenomatous polyposis coli gene: identification of an alternatively spliced transcript | |
| Arai-Takahashi | The Right to Health in International Law; A Critical Apprasial | |
| Barankiewicz et al. | Regulation of adenosine concentrations and attenuation of ischemia by novel reversible ADA inhibitors | |
| Foster | Garcinia | |
| Reimers | Ne Absorption Lines in the Spectrum of the QSO HS 1700+ 6416 | |
| Ogata et al. | Activation of nuclear factor-kappa B in human endothelial cells by oxygen free radicals. | |
| Pell | Arts and Humanities: Pell Statement (January 27, 1976): Speech 01 | |
| Su et al. | Modeling spontaneous and evoked glutamate release of NMDA receptors |